Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery
Conditions
Interventions
Intervention1: Evermine 50-50μm Everolimus-Eluting Coronary Stent System: Everolimus-Eluting Coronary Stent System
Control Intervention1: NIL: NIL
Sponsors
Meril Life Sciences Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. The subject must be at least 18 years of age at the time of signing the informed consent. 2. The subjectâ??s legally authorized representative agrees to the subjectâ??s participation in this study and signs the informed consent form. 3. The subject who agree to participate in the study. 4. Only Evermine 50 EES stent(s) is (are) implanted during the index procedure. 5. The subject whose coronary artery is suitable for implantation of Evermine 50 EES. 6. Female subjectâ??s of childbearing potential who does not plan pregnancy for up to 2 years from the date of index procedure. For a female subject of childbearing potential a pregnancy test must be performed with negative results at screening visit. 7. Female subject is not breast-feeding at the time of the screening visit and will not be breast-feeding for up to 2 years from the date of index procedure. 8. Subject agrees not to participate in any other investigational or invasive clinical study for a period of 2 years from the date of index procedure
Exclusion criteria
Exclusion criteria: 1. The inability to obtain an informed consent. 2. Subject with known hypersensitivity or allergies to aspirin, heparin, Everolimus, polymer lactide, Cobalt-chromium metal and glycolide antiplatelet drugs (clopidogrel, prasugrel etc). 3. Female subject with known pregnancy or who are lactating at the time of screening
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Major Adverse Cardiac Events (MACE), Ischemic Driven Target Lesion Revascularization(ID-TLR) Timepoint: 1 month (±14 days), 6 months (±28days), 12 months (±28 days) and 24 months (±28 days) | — |
Secondary
| Measure | Time frame |
|---|---|
| Ischemic Driven Target Vessel Revascularization (ID-TVR), Procedural success, Device SuccessTimepoint: 1 month (±14 days), 6 months (±28 days), 12 months (±28 days) and 24 months (±28 days) | — |
Countries
India
Contacts
Public ContactDr Suresh V Patted
KLES Heart Foundation
Outcome results
None listed